Renowned Geneticist Philip Beales Launches Axovia Therapeutics to Develop Transformative Medicines for Ciliopathies
Axovia is a majority-owned subsidiary of Jaguar Gene Therapy, which is backed by Deerfield Management
LONDON, Feb. 25, 2021an innovative gene therapy company developing disease-transformative medicines for ciliopathies, led by renowned researcher Professor Philip Beales, launched today after being in stealth mode for the past year. Axovia is a majority-owned subsidiary of Jaguar Gene Therapy, which is backed by Deerfield Management, and is also partially funded by
UCL Technology Fund. Axovia is receiving initial operational support from Jaguar Gene Therapy, including critical manufacturing guidance intended to expedite Axovia s development timelines and enable it to bring its much-needed discoveries to patients.
Former AveXis executives launch gene therapy startup with uncommon targets
biopharmadive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharmadive.com Daily Mail and Mail on Sunday newspapers.
Investegate |Axovia Therapeutics Announcements | Axovia Therapeutics: Renowned Geneticist Philip Beales Launches Axovia Therapeutics to Develop Transformative Medicines for Ciliopathies
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Xilio plans to file INDs for its two lead candidates this year. (PDPics/Pixabay)
Xilio Therapeutics has raised $95 million to take IL-2 and CTLA-4 immunotherapies into clinical trials. The series C positions Xilio to provide early clinical validation of anti-cancer agents that are designed to remain inactive until they reach tumors.
Immuno-oncology drugs are typically given systemically, causing them to trigger immune responses that affect healthy and cancerous tissues alike. The resulting adverse events are unpleasant and can prevent physicians from administering the most efficacious dose. Patients suffer from both the side effects and worse outcomes due to the use of suboptimal doses.